한국 유전체 코호트 구축의 전략적 고려사항 = Strategy Considerations in Genome Cohort Construction in Korea

다국어 초록 (Multilingual Abstract)

Focusing on complex diseases of public health significance, strategic issues regarding the on-going Korean Genome Cohort were reviewed: target size and diseases, measurements, study design issues, and follow-up strategy of the cohort. Considering the epidemiologic characteristics of Korean population as well as strengths and drawbacks of current research environment, we tried to tailor the experience of other existing cohorts into proposals for this Korean study. Currently 100,000 individuals have been participating the new Genome Cohort in Korea. Target size of de novo collection is recommended to be set as between 300,000 to 500,000. This target size would allow acceptable power to detect genetic and environmental factors of moderate effect size and possible interactions between them. Family units and/or special subgroups are recommended to parallel main body of adult individuals to increase the overall efficiency of the study. Given that response rate to the conventional re-contact method may not be satisfactory, successful follow-up is the main key to the achievement of the Korean Genome Cohort. Access to the central database such as National Health Insurance data can provide enormous potential for near-complete case detection. Efforts to build consensus amongst scientists from broad fields and stakeholders are crucial to unleash the centralized database as well as to refine the commitment of this national project.

참고문헌 (Reference)

1 Hakonarson H, "deCODE genetics, Inc" 4 (4): 209-215, 2003

2 Sung JH, "Years of life lost and health priority in Korea" 19 (19): 200-209, 1997

3 Ollier W, "UK Biobank: from concept to reality" 6 (6): 639-646, 2005

4 Potter JD, "Toward the last cohort" 13 (13): 895-897, 2004

5 Murray CJ, "The global burden of disease in 1990: summary results, sensitivity analysis and future directions" 495-509,

6 Collins. FS, "The case for a US prospective cohort study of genes and environment" 429 (429): 475-477, 2004

7 Ronningen KS, "The biobank of the Norwegian mother and child cohort Study: A resource for the next 100 years" 21 (21): 619-625, 2006

8 Kim HJ, "Smoking and colorectal cancer risk in the Korean elderly" 39 (39): 123-129, 2006

9 Ebrahim S, "Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study" 333 (333): 22-, 2006

10 Almasy L, "Multipoint quantitativetrait linkage analysis in general pedigrees" 62 (62): 1198-1211, 1998

11 Abecasis GR, "Merlin - rapid analysis of dense genetic maps using sparse gene flow trees" 30 (30): 97-101, 2002

12 Collins FS, "Merging and emerging cohorts: necessary but not sufficient" 445 (445): 259-, 2007

13 Willett WC, "Merging Merging and emerging cohorts: not worth the wait" 445 (445): 257-258, 2007

14 Carlson CS, "Mapping complex disease loci in wholegenome association studies" 429 (429): 446-452, 2004

15 Triendl R, "Japan launches controversial Biobank project" 9 (9): 982-, 2003

16 Yoo KY, "Genomic epidemiology cohorts in Korea: Present and the future" 6 (6): 238-243, 2005

17 Bentley DR, "Genomes for medicine" 429 (429): 440-445, 2004

18 Peltonen L, "GenomEUtwin: A strategy to identify genetic influences on health and disease" 6 (6): 354-360, 2003

19 Manolio TA, "Genes, environment and the value of prospective cohort studies" 7 (7): 812-820, 2006

20 Glazier AM, "Finding genes that underlie complex traits" 298 (298): 2345-2349, 2002

21 Jun JK, "Fasting serum glucose level and gastric cancer risk in a nested case-control study" 39 (39): 493-498, 2006

22 Terwilliger JD, "Confounding, and the blind quest for a genetic fountain of youth" 35 (35): 532-544, 2003

23 Jee SH, "Body-mass index and mortality in Korean men and women" 355 (355): 779-787, 2006

24 Sung J, "A twinfamily study of Korea - Protocols and current status" 9 (9): 844-848, 2006